We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KSU
426
DELISTED
Kansas City Southern
KSU
| $16.8M | 0.04% |
112,500
+2,400
| +2% | +$337K |
|
427
Novavax
NVAX
$1.27B
| $16.6M | 0.04% |
+199,600
| New | +$7.63M |
|
428
Healthpeak Properties
DOC
$15B
| $16.6M | 0.04% |
603,143
+44,000
| +8% | +$1.12M |
|
429
Ball Corp
BALL
$16.9B
| $16.5M | 0.04% |
237,797
+67,483
| +40% | +$4.56M |
|
430
Axsome Therapeutics
AXSM
$11B
| $16.5M | 0.04% |
200,000
+115,000
| +135% | +$8.85M |
|
431
Keysight
KEYS
$57.4B
| $16.4M | 0.04% |
162,825
-900
| -0.5% | -$88.3K |
|
|
VNTR
432
DELISTED
Venator Materials PLC
VNTR
| $16.4M | 0.04% |
9,156,202
| – | – |
|
433
Incyte
INCY
$24.3B
| $16.3M | 0.04% |
157,002
+14,300
| +10% | +$1.38M |
|
434
Domino's
DPZ
$12.1B
| $16.2M | 0.04% |
+43,973
| New | +$16.2M |
|
435
Comstock Resources
CRK
$3.81B
| $16.2M | 0.04% |
+3,700,000
| New | +$22.1M |
|
436
Advanced Drainage Systems
WMS
$11.5B
| $16.1M | 0.04% |
326,670
+226,670
| +227% | +$9.31M |
|
437
Valero Energy
VLO
$87.1B
| $16.1M | 0.04% |
273,300
-208,000
| -43% | -$12.4M |
|
438
Abeona Therapeutics
ABEO
$388M
| $16M | 0.04% |
220,000
| – | – |
|
|
MRNS
439
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $16M | 0.04% |
1,575,000
+375,000
| +31% | +$3.45M |
|
440
Boston Properties
BXP
$11.2B
| $15.8M | 0.04% |
174,918
-15,600
| -8% | -$1.42M |
|
441
International Paper
IP
$22.4B
| $15.8M | 0.04% |
472,974
-8,342
| -2% | -$266K |
|
442
RingCentral
RNG
$5.16B
| $15.7M | 0.04% |
+55,000
| New | +$13.9M |
|
443
Cenovus Energy
CVE
$51.1B
| $15.6M | 0.04% |
3,350,000
+3,100,000
| +1,240% | +$11.9M |
|
444
Broadridge
BR
$18.9B
| $15.6M | 0.04% |
+123,900
| New | +$14.3M |
|
|
HES
445
DELISTED
Hess
HES
| $15.6M | 0.04% |
+301,700
| New | +$13.8M |
|
|
CHMA
446
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $15.6M | 0.04% |
2,900,000
| – | – |
|
447
Nasdaq
NDAQ
$52.9B
| $15.6M | 0.04% |
391,740
+7,800
| +2% | +$290K |
|
448
Syndax Pharmaceuticals
SNDX
$1.77B
| $15.6M | 0.04% |
1,050,000
+50,000
| +5% | +$762K |
|
449
Oneok
OKE
$55B
| $15.5M | 0.04% |
466,700
-9,900
| -2% | -$323K |
|
|
AMTD
450
DELISTED
TD Ameritrade Holding Corp
AMTD
| $15.5M | 0.04% |
425,500
-1,000,000
| -70% | -$37.6M |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.